NasdaqCM:IMNMBiotechs
H.C. Wainwright Coverage Puts Immunome Oncology Pipeline And Execution In Focus
H.C. Wainwright has initiated analyst coverage on Immunome, focusing on its oncology pipeline and overall positioning.
The coverage launch brings additional attention to Immunome’s approach to cancer therapeutics and its progress as a NasdaqCM:IMNM listed company.
Immunome, trading on NasdaqCM:IMNM, last closed at $22.425, with a 1 year return of 115.0% and a 3 year return that is roughly 4x. Over the past 30 days, the stock shows an 11.3% return, while the 7 day return reflects a 6.6%...